

3rd Annual Southern California Genitourinary Cancer Research Forum

Summary of Thoughts from the Uromigos

Thomas Powles, MD, MRCP

Professor of Genitourinary Oncology

Director, Barts Cancer Centre at St. Bartholomew's Hospital

Brian Rini, MD

Professor, Department of Medicine

Vanderbilt University

Disclosures

Thomas Powles, MD, MRCP

Professor of Genitourinary Oncology
Director, Barts Cancer Centre at St. Bartholomew's
Hospital

- *Consultant for AstraZeneca, Bristol-Myers Squibb, Exelixis, Ipsen, MSD, Novartis, Pfizer, Astellas, Eisai, Roche*

Brian Rini, MD

Professor, Department of Medicine
Vanderbilt University

- *Consultant for Merck, Eisai, and Formedics*

This presentation and/or comments will be free of any bias toward or promotion of the above referenced companies or their product(s) and/or other business interests.

This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.

This presentation has been peer-reviewed and no conflicts were noted.

Cultural Linguistic Competency (CLC) & Implicit Bias (IB)

STATE LAW:

The California legislature has passed Assembly Bill (AB) 1195, which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed AB 241, which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

EXEMPTION:

Business and Professions Code 2190.1 exempts activities which are dedicated solely to research or other issues that do not contain a direct patient care component.

This presentation is dedicated solely to research or other issues that do not contain a direct patient care component.

3rd Annual Southern California Genitourinary Cancer Research Forum

Summary of Thoughts from the Uromigos

Thomas Powles, MD, MRCP

Professor of Genitourinary Oncology

Director, Barts Cancer Centre at St. Bartholomew's Hospital

Brian Rini, MD

Professor, Department of Medicine

Vanderbilt University